Menopur (Menotrophin)

Menotropin contains both FSH and LH activity. FSH stimulates granulosa cells to promote follicle growth and estrogen production, while LH acts on theca cells to support androgen conversion and trigger ovulation. Together they coordinate the development and release of oocytes during the menstrual cycle.

The dose of Menopur is individualized by the prescribing clinician based on the patient’s ovarian response, age, body weight and treatment protocol. Physicians calculate the appropriate number of IU per day and adjust it according to monitoring results such as ultrasound and hormone levels.

Menopur is not indicated for use during an established pregnancy and its safety in breastfeeding has not been established. It should only be used under strict medical supervision before conception, and women are advised to avoid breastfeeding while undergoing treatment.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

The primary alternative to Menopur is recombinant FSH products such as follitropin alfa (Gonal‑F). Menopur provides both FSH and LH activity in a single preparation, potentially reducing the need for separate LH supplementation, whereas recombinant FSH contains only FSH and may require an additional LH product for optimal response.

Menopur should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. After reconstitution, the solution should be used within the time frame specified in the product label and kept refrigerated until administration.

Menopur is supplied as a powder that must be reconstituted with the provided diluent. The resulting solution is injected either intramuscularly or subcutaneously, typically once daily, according to the dosing schedule determined by the treating physician.

Serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, abdominal pain and shortness of breath; multiple pregnancy; thromboembolic events; allergic reactions including anaphylaxis; ovarian torsion; and ectopic pregnancy. Prompt medical attention is required if any of these occur.

Menopur is contraindicated in women with known hypersensitivity to menotropin or any excipients, in those with uncontrolled thyroid or adrenal disease, in patients with ovarian cysts or ovarian enlargement unrelated to treatment, and in individuals who are already pregnant. It should also be used with caution in patients at high risk for thromboembolic events.